Overcoming the obstacles to clinical evaluation of 211at-labeled radiopharmaceuticals

Journal of Nuclear Medicine

Volumn 42, Issue 10, 2001, Pages 1516-1518

  Wilbur, D S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211;

ALPHA RADIATION; CANCER THERAPY; EVALUATION; ISOTOPE LABELING; NOTE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANIMALS; ASTATINE; CLINICAL TRIALS; DRUG EVALUATION; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 0034800373     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (41)

1. Radioastatine: Possible uses of a heavy halogen
2. Astatine-211: Its possible applications in cancer therapy
3. Alpha particle radio-immunotherapy: Animal models and clinical prospects
4. Alpha-particle emitters in medicine
5. Potential use of alpha-emitting radionuclides in the treatment of cancer
6. Targeted therapy using alpha emitters
7. 211At
8. Alpha-emitters for medical therapy: Workshop of the United States Department of Energy
9. 211At-labeled antibodies for clinical use
10. 211At-labelled human serum albumin microspheres: Preliminary clinical experience
11. Artificially radioactive element 85
12. The accumulation, metabolism and biological effects of astatine in rats and monkeys
13. The accumulation and destructive action of astatine-211 (EKA-iodine) in the thyroid gland of rats and monkeys
14. Studies on the thyroidal uptake of astatine in the rat
15. Radioiodine therapy of thyroid disease
16. Monoclonal antibodies: Their chemistry, functions, and possible uses
17. 211At labelled monoclonal antibody with known specificity in a murine system
18. The nature of the astatine-protein bond
19. Preparation of a biologically stable and immunologically competent astatinated protein
20. 211At using an acylation reaction
21. 211At-IgG conjugate which is stable in vivo
22. The preparation of aromatic astatine compounds through aromatic mercury-compounds
23. 2 fragments with the α-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity
24. Reactions of organometallic compounds with astatine-211: Application to protein labeling
25. Tumor incidence in normal Sprague-Dawley female rats
26. The induction of tumors in the rat by astatine-211
27. Toxicity of astatine-211 in the mouse
28. 211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: A long-term survival study with histologic analysis
29. Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis
30. Production, isolation, and purification of astatine isotopes
31. 211 At reaction
32. Astatine-211-tellurium radiocolloid cures experimental malignant ascites
33. 90Y
34. 211At in a murine intraperitoneal tumor model
35. 211At-labelled monodisperse polymer particles in vivo: Comparison of different specific activites
36. 1311-methylene blue: Preclinical and clinical experience
37. 211At]-astatinated endoradiotherapeutic drug. IV. Late radiation effects
38. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211
39. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation
40. 211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model
41. Radioiodination and astatination of octreotie by conjugation labeling